Clinical Trial Update: Predictors for Response to Dose-dense Docetaxel and Epirubicin Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating predictors of response to dose-dense docetaxel and epirubicin in Stage III breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: University of Bergen | Conditions: Stage III Breast Cancer AJCC V7 | Phase 2 | Status: ACTIVE_NOT_RECRUITING